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WTO deeisions reaardig the EC hormones ban 
The  objective  of this  Communication  is  to  examine  the  various  possible  options 
concerning the ban on the import of beef from animals- which have been treated with 
hormone growth promoters. 
The  Commission stresses that this Communication deals  only  with the ban on the 
imports  of beef from  animals  which  have  been  treated  with  hormone  growth 
promoters.  The  question  of the  ban  on  the  use  of such  substances  within  the 
Community  is not addressed  by  the  WTO judgement which  has  given rise to the 
present problem. 
The options discussed are interim measures addressing the present problem of timing 
due to the fact that the WTO decided that the Community should bring its measures in 
conformity with the provisions of the Sanitary and Phytosanitary Agreement (SPS) 
within a "reasonable period of  time" that expires on the 13'h of  May 1999. 
It also stresses that final decisions on the Community's policies on hormones can only 
be taken on a science base and therefore when the results of the risk assessment are 
available  and that this  Communication  is  intended,  in  particular,  to  deal  with the 
situation in which the Community now finds  itself, in the run-up to  the end of the 
"reasonable period". 
l.  Bacyround 
On  13  February, 1998  the  Dispute  Settlement  Body  (DSB)  of the  World  Trade 
Organisation adopted the Appellate Body Report and the Panel Reports, as modified 
by  the Appellate Body Report,  regarding "EC  Measures concerning meat and  meat 
products (Hormones)". The Appellate Body recommended that "the OSB  request the 
European Communities to bring the SPS measures found ... to be inconsistent with the 
Sanitary  and  Phytosanitary  Agreement  into conformity  with the  obligations of the 
European  Communities  under  that  Agreement".  The  Community  indicated  that  it 
1 intended  to·  fulfil  its  obligations  under  the  wro,  and  that  it  would  require  a 
reasonable period of  time to do so. 
The Appellate Body had  found that the Community had provided "general  studies 
which do indeed show the existence of  a general risk of  cancer;  but they do not focus 
on and do not address the particular kind of risk here at stake - the carcinoaenic or 
genotoxic potential of the residues of those honnones found in meat derived from 
cattle  to  which  the  honnones  had  been  administered  for  growth  promotion 
purposes  ...  those general studies are in other words relevant but do not appear to be 
sufficiendy specific to the case at hand." 
The Dispute Settlement Understanding (DSU) foresees in its Article 21.1 that "Prompt 
compliance with recommendations or rulings of the DSB is essential ...  ", but it also 
recognises that this may not be possible. In Article 2 J  .3, therefore, it provides that 
" ... If it  is  impracticable  to  comply  immediately  with  the  recommendations  and 
rulinas, the Mem~r  concerned shall have a reasonable period of  time in which to do 
so.  That period of time shall be  agreed  between the parties or,  in  the absence of 
agreement, decided by an Arbitrator. The guideline for the Arbitrator is laid down as 
fifteen  months,  but it is also  provided  that  this  period  can be shorter or longer, 
depending upon the particular circumstances. 
Followina unsuccessful efforts tO agree a reasonable period with the US and Canada. 
an Arbitrator was appointed to detennine that reasonable period. 
The  Community indicated that its intention was to conduct honnone specific and 
residue specific risk assessment for all the 6 honnones in question, as clarified by the 
Appellate Body, and, in the light of  the results, to review the measure. We indicated 
that the risk assessment would require some two years, followed by approximately 1  S 
months for any legislative process, which would be by co-decision. 
The US and Canada· argued that the DSB had ruled that there was no human health 
basis to the ban, which should therefore be removed. 
The Arbitrator  recalled the following points: 
•  The panels and  Appellate  Body  recommended  that  the  Community  bring  its 
measures, which  we~ found  to be inconsistent with the SPS Agreement,  into 
conformity with its wro  obli~ations. 
•  Although Article 19.1 of the DSU provides that the Panel or Appellate Body can 
sugaest ways in which this decision cun be implemented, they did not do so. 
•  The Appellate Body concluded that the  EC  provision was  not  based on u risk 
assesSment in accordance with the provisions of  the SPS Agreement. 
The Arbitrator stated that commissioning of scientific studies or consultations with 
experts were not considerations pertinent to the determination of  the reasonable period 
of  time, and could not justify a period of  time longer that the· guideline laid down in 
Article 21.3 of the DSU. Regarding the legislative process, the Arbitrator stated that 
under curreilt  EC law, a  proposal to repeal  or modify the  ban,  both  intemally and 
externally, could be taken  under Article 43 of  the Treaty;  but he was "mindful" that 
2 when the  Amsterdam  Treaty enters  into  force  (which  at  that  time  was considered 
likely to be as early as January 1999), co-decision will be necessary. 
On  that  basis,  the  Arbitrator  granted  the  Community a  "reasonable  period"  of 15 
months (from the adoption of the rulings and recommendations on  13  February last) 
to implement those rulings and recommendations- that is, untill3 May 1999. 
In  line  with  the  intention  indicated  above,  the  Commission  has  initiated  a 
complementary risk assessment last year. In order to improve and complement recent 
scientific  evidence  regarding  the  potential  adverse  effects  on  human  health  of 
hormone residues in meat, and at the same time respond to the criticism by the WTO 
Appellate Body concerning the scientific basis of  the EC import ban, a number of  new 
scientific studies were commissioned (see annex). Work on these started as early as 
February  1998.  Final  results  from  most  of these  projects  are  expected  to  become 
available in the course of 1999, while others will terminate only in 2000. Intermediate 
results are foreseen· at an earlier stage for all projects. 
Meanwhile, on the basis of data which has become available in recent years, and the 
final. or interim results available from  the  new studies, the appropriate independent 
scientific  committee  (the  Scientific  Committee  on  Veterinary  Matters  relating  to 
Public Health, SCVPH) has been requested to  deliver an opinion before the end of 
April 1999, responding as far as possible to a number of  questions intended to clarify 
what  potential  adverse  effects  may  arise  from  residues  in  bovine  meat  and  meat 
products, resulting from the use of the 6 hormones in question for growth promotion 
in cattle. It must be noted that the conclusions of the risk assessment may differ for 
each of  the 6 substances and, therefore, the Community policy in each case may differ 
accordingly. In accordance with the rulings of  the Appellate Body, the Commission's 
risk assessment will  also take into account risk arising from difficulties of control, 
inspection and enforcement of  the requirements of  good veterinary practice. 
If  the SCVPH is unable to give a conclusive opinion in April, it will be requested to 
complete its opinion as soon as possible in the light of  the new studies. 
3.  Community interest 
The Community has two key interests which are relevant in this affair: 
(a)  It must ensure a high level of consumer health protection and it must ensure 
that  an  objective,  transparent  and  reliable  procedure  is  foJJowed  for  the 
evaluation of the risk in question. 
(b)  It must respect its obligations under the WTO, including the SPS Agreement, 
inter alia, in light of  its attachment to the dispute settlement procedures of  the 
WTO and because it is in our interest that other members of the SPS do not 
erect artificial barriers against our exports. 
The SPS Agreement, as clarified by the Appellate Body ruling taken as a whole, does 
not involve any conflict between these two objectives, as it is clear that signatories of 
the SPS retain the sovereign right to determine their own level of health protection, 
3 provided that any trade restricting measures to enforce that chosen level of protection 
are  reasonably  supported  by  a  risk  assessment.  But,  in  this  specific  case,  the 
Community flees a difficult problem of  timing, due to the fac:t that there is at present 
a ban in place on imports and, until a risk assessment is performed that also fulfils the 
requirements under the  SPS Aareement.  as clarified by  the Appellate Body, it  can 
neither be defended internationally nor easily concluded that it can be modified. 
At this point in time it is not possible to estimate, with any degree of certainty, the 
time frame within which scientific advice of  the SCVPH permitting the conclusion of 
a risk  assessment will  be available.  The Community  may,  therefore,  not be in a 
-position  to  meet  the  13  May  deadline.  It  is  against  this  background  that  this 
Communication has been prepared. 
4.  Implieatiou of failill1 to bria1 our lgislation into conformity by the ead of 
the reuoaaltle perlecl 
The  DSU  is  clear  that  the  preferred  outcome  is  conformity  by  the  end  of the 
reasonable  period.  It nevertheless recognises that this may not always happen and 
provides two possible measures which are  av&ilable  to deal with a  situation where 
conformity  has  not  been  achieved  by  then.  One  is  compensation.  Article  22.2 
provides
1
,  inter alia, that if  a member has not complied within the reasonable period 
of time  that  member  should,  if so  requested,  enter  into  negotiations  with  the 
complainina  parties  in  order  to  agree  temporary  compensation.  The  other  is 
withdrawal of  concessions by the complaining parties. The level of the withdrawal of 
concessions and the sectors on which it falls is decided by the complaining parties, 
subject to a ript of arbitration on the level of the withdrawal of concessions. Such 
suspension of  concessions or other obligations shall only be applied until the measure 
found to be inconsistent has been  removed or a  mutually  satisfactory solution has 
been found (Article 22.8 of  the DSU). 
5.  Optiou available to the Community iD the present aituatioa 
In order to prepare the possible situations which may apply from the end of April or 
early May when interim results of  the Commission's risk assessment are expected and 
the  "reasonable  period"  expires,  the  following  options  (which  are  not  mutually 
exclusive) can be considered: 
( l)  The Commission could encourage the complainants to enter inlo negotiation 
on compensation. "Compensation" in this context means trade conccsNions and 
Artict. 22.2 of  the DSU: "lfthe Member concerned fails to bring the measure found to be 
inconsistent with a covered agreement into compliance therewith or otherwise comply with the 
recommendation and rulinp within the reasonable period of  time determined pursuant to. paraifaph 3 
of  Article 21, such Member shall, if  10 requested, and no later than the expiry of  the reasonable period 
of  time, enter into negotiations with any party having invoked the dispute settlement procedures, with a 
view to developing mutually acceptable compensation. If no satisfactory compensation has been 
apeed within 20 days after the date of  expiry of  the reasonable period of  time. any party having 
invoked the dispute settlement procedures may ~st  authorization from the DSB to suspend the 
application te th8 Member concerned of  cencessions or ocher obliptioM under the covered 
qreements." 
4 it  is  likely  that,  if the  complainants .are  prepared  to  consider compensation, 
they will insist that all or most of it would be in the agricultural sector, as this 
is  the  sector  which  is  affected  by  our  ban.  Compensation  could  include 
increased access to Community markets. The final position of the Community 
would be defined in light of  the risk assessment. 
(2)  The Community could, in accordance with Article 5.7 of the SPS Agreement
2
, 
provisionally,  adopt  sanitary  measures  "on  the  basis  of available  pertinent 
information". Such a measure would not change the substance of the present 
prohibition  but  only  transform  it  into  a  provisional  one  and  it should  be 
accompanied by further efforts to obtain the additional information necessary. 
Preparation to take action, hereunder in accordance with Article 5.7, could be 
initiated already now. 
(3)  The Commission could propose  to  lift  the  ban on imports  provided that a 
suitable  labelling  scheme could  be  introduced  which  enabled consumers to 
recognise the beef concerned and avoid  it, if  they so chose.  Such a  proposal 
could be prepared already now, but would be  put in  place depending on  the 
interim results of  the risk assessment and thereafter kept under review. 
Community  actions  in  this  field  will  require  full  information  and  political 
involvement  of the  Council  and  the  European  Parliament.  Early  preparation  of 
proposals for legislation under options (2) and (3), allowing the Commission to act on 
the basis of  the interim results of  the risk assessment, could permit the Community to 
act  quickly  also  during the  period of election and  reconstitution of the  European 
Parliament. 
6.  Advantages and disadvantages of these options 
The advantage of option (l) is that it offers the prospect of acting in agreement with 
the complainants and hence allowing the scientific studies and the risk assessment to 
be  concluded  in  a  calm  atmosphere,  thus  optimising  the  chances  of the  risk 
assessment being generally perceived as being correct and objective, both by our own 
citizens and by the complainants. If temporary compensation is agreed, it would have 
the advantages that we would have influence on the choice of  sectors to be affected by 
tariff measures and that it could be terminated rapidly as soon as the Community had 
an adequate scientific basis to take a decision. The amount of compensation likely to 
be agreed with the complainants can be expected to be significant, but it would be the 
result  of an  agreement.  In  contrast,  the  Community's  influence  on  a  retaliatory 
measure would be limited to the right to challenge the amount in a WTO arbitration. 
We cannot, however, be certain that it will prove to be negotiable. 
Article 5.7 of  the SPS Agreement: "In cases where relevant scientific evidence is insufficient, 
a Member may provisionally adopt sanitary or phytosanitary measures on the basis of  available 
pertinent information, including that from the relevant international organizations as well as from 
sanitary or phytosanitary measures applied by other Members. In such circumstances, Members shall 
seek to obtain the additional information necessary for a more objective assessment of risk and review 
the sanitary or phytosanitary measure accordingly within a reasonable period of lime." 
5 Option (2) allows the Community to  act,  in  accordance with  Article  5. 7 of the SPS 
Agreement, on the basis of "available pertinent evidence"  whenever it  may become 
available  and  thereby  to  reduce  to  a  minimum  the  period  during  which  the 
Community  risks  not  being  in  conformity  with  its  SPS  obligations.  "Available 
pertinent evidence" could be "scientific evidence coming from qualified and respected 
sources"
3  or relevant  evidence  arising  from  difliculties  of control,  inspection  and 
enforcement
4
•  Unfortunately, the complainants appear,  in any case, ready to contest 
the view that transfonnation of  the ban into a provisional measure could, against the 
background of this dispute, ever be regarded as bringing us into conformity with our 
obligations.  Therefore,  a  damaging  trade  dispute  is  likely. to  emerge  despite  the 
strength of  the Community's arguments. 
Option (3)  has  the  advantage  that  it  would  bring  the  Community  as  quickly  as 
possible into a position where, in the eyes of all relevant parties, it was in conformity 
with its obligations. This would avoid the need to provide compensation or suffer loss 
of concessions and it would enhance the Community's own ability to  insist on  the 
strict application of WTO agreements by  other countries.  But this  option  has  the 
disadvantage (depending on the preliminary results of the scientific studies which are 
now in progress) that it might involve allowing onto the market a  product which, 
hitherto we have considered to pose a potential risk.  This action would take place 
prior to completion of the further studies which are currently underway to determine 
the reality of that risk, a decision which subsequent scientific results might put into 
question. Moreover, it may prove difficult to design a suitable labelling scheme which 
would not be contested by the complainants in the WTO. 
If the Community refrained from  or failed  to take appropriate legislative action as 
well as to negotiate compensations, the complainants will,  in  all  likelihood, obtain 
authorisation to implement sanctions in  the form of  withdrawal of concessions. This 
situation , although arguably less conflictual than option (2), is, however, likely to 
deprive the Community of  the possibility to influence the measures that will be taken 
by the complainants. 
7.  Options in a time penpeetive 
The options presented above are not mutually exclusive. On the contrary, they can be 
situated in a scenario as follows: 
•  It  is  clear  that  the  Community's  final  position  on  the  prohibition  can  be 
established only after the definitive conclusion of the  current risk  assessment. 
The time likely to be needed to arrive at such a conclusion poses, however, a 
problem of  managing the intermediary period. 
•  On the basis of  current information, the Commission expects to dispose, towards 
the end of April  or early May, of interim  results of the  risk  assessment.  It is 
likely  that these  results  may  not  be  suflicient  for  the  Community  to  take  a 
Appellate Body report, paragraph 194. 
Appellate Body report, paragraph  205. 
6 position on  the  current  prohibition.  In  that  case,  the  risk  assessment  will  be 
continued. 
•  In light of this, it appears that option ( 1  ), i.e. negotiations with the complainants 
concerning temporary compensations, should be pursued without further delay. 
•  It is possible that, by the end of April or early May, the interim conclusions of 
the risk assessment will allow a fundamental re-evaluation of the situation; but it 
is also possible that it will prove necessary to await the definitive results of the 
risk assessment.  In this last case, payment of temporary compensations would 
have to  be  made  until  such  definitive  results  of the  risk assessment  become 
available and a definitive decision is taken. 
•  At any moment, the situation could be re-examined in terms of  the three options 
mentioned in paragraph 5. 
8.  Conclusion 
The  Commission  invites  the  Council  and  the  European  Parliament  to  urgently 
consider the options presented as well as their articulation over time with a view to 
determine their implementation up to and during the interim period. 
In  any  case,  the  Commission  will  initiate  preliminary  discussions  with  the 
complaining parties in order to further evaluate the merits of  the different options, and 
in particular will explore the feasibility of  compensation  . 
•  • 
• 
7 Annex 
The study programme initiated by the European Commission on six hormones used 
for animal growth promotion 
The  European  Commission  has  approved  and  financed  a  number  of research 
projects on potential adverse human health effects arising from  the usc of the six 
hormones estradiol-17J3, progesterone, testoterone, zeranol, trcnbolone acetate and 
melengestrol acetate and their metabolites for growth promotion purposes.  Final 
results from most of  these studies are expected to become available in the course of 
1999,  while  some  projects  will  be  finished  in  2000.  Intermediate  results  are 
foreseen at an earlier stage for all studies. The studies are the following: 
One study is analysing the potential genotoxicity of a metabolite of  oestradiol 17J3 
in bovine meat and evaluating the  potential health  risks  to consumers from  the 
relevant residues in meat. 
One study is analysing the potential genotoxicity and  mutageni~ity of the parent 
compounds  trenbolone  acetate  and  zeranol,  and  some  of their  metabolites. 
Residues extracted from bovine meat will  be  used to perform in vitro and in vivo 
studies. This project will also evaluate the potential risks to human health from the 
presence of  residues of  these two hormones in meat. 
One study is a comprehensive study of the potentially genotoxic metabolites of 
oestradiol  17J3  and the  potential risks of cancer to consumers arising from  such 
residues  in  meat.  The  potential  risks  from  misuse  or failure  to  observe  good 
veterinary practice in the administration of  oestradiol 17P will also be examined. 
This study is a collaboration of  several research experts and laboratories, in view of 
the wide range of  the experimental research involved. 
One study will concentrate on melengestrol acetate, but will also search for other 
metabolites of trenbolone acetate and zeranol not covered by the second project 
mentioned above. The carcinogenicity and genotoxicity of the parent compounds 
and their metabolites will be tested in vitro and in  vivo.  Potential risks to human 
health from residues in meat will be evaluated. 
One study is focusing on the gene expression of low levels of zeranol in order to 
assess potential adverse human health eflt.:cts of  this substance. 
A number of studies have been initiated to  provide residuc-spccilic results.  while 
potential risks to human health resulting  from  misuse and  failure  to  respect good 
veterinary practice in the administration of  all six hormones are also studied. This 
covers possible misuse and disregard of  good veterinary practice. 
Furthermore,  a  number  of studies  on  the  direct  and  indirect  effects  on  the 
environment  and  wildlife  (such  as  degradation  kinectics,  presence  in  the 
environment, effects on animals) and the implications for human health have been 
8 initiated. An epidemiological study on potential adverse endocrine effects is also 
underway. 
In  total,  17  research  studies  related  to  honnones  have  been  initiated  by  the 
Commission. 
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